Financing Alternatives for Life Sciences Companies

The U.S. capital markets remain an attractive source of capital for emerging companies in the life sciences sector. Approximately 21.7% of the 2017 IPOs were life sciences companies. Many of these IPOs were preceded by late stage (or mezzanine) private placements made principally to U.S. institutional investors.

During our webinar, Steve Maletzky (William Blair), along with partners David Bakst and Anna Pinedo will discuss:

• Financing alternatives for pre-IPO companies;
• The late-stage (or “cross-over”) private placements market;
• Considering milestones when planning a financing strategy;
• Post-IPO alternatives, including registered direct offerings, PIPE transactions, at the market offerings, and related financing considerations.

CLE credit will be provided. For more information, or to register for this session, please visit the event website.

---

CLE is not available when viewing a recording of this program. In order to receive credit you must have attended the live webinar program.